Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Deligne

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Medecine Sciences : M/S|January 7, 2020
[Anti-tumor monoclonal antibodies: new insights to elicit a long-term immune response]Claire Deligne, Laurent Gros
Frontiers in Oncology|March 15, 2021
Macrophages and Extracellular Matrix in Breast Cancer: Partners in Crime or Protective Allies?Claire Deligne, Kim S Midwood
Medecine Sciences : M/S|January 29, 2013
[The Janus face of monoclonal antibodies in oncology: passive immunity and vaccination]Claire Deligne, Jean-Luc Teillaud
Journal of Personalized Medicine|April 23, 2022
Personalized Immunotherapies for Type 1 Diabetes: Who, What, When, and How?Claire Deligne, Sylvaine You, Roberto Mallone
Frontiers in Immunology|September 1, 2017
Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?Claire Deligne, Benoît Milcent, Nathalie Josseaume, et al.
Frontiers in Immunology|August 27, 2021
Oral Fc-Coupled Preproinsulin Achieves Systemic and Thymic Delivery Through the Neonatal Fc Receptor and Partially Delays Autoimmune DiabetesNoémie Corcos, Slobodan Culina, Claire Deligne, et al.
Methods in Cell Biology|January 10, 2018
How to detect and purify tenascin-CSean P Giblin, Devadarssen Murdamoothoo, Claire Deligne, et al.
European Journal of Immunology|December 20, 2024
Half-Life Extension of the IgG-Degrading Enzyme (IdeS) Using Fc-Fusion TechnologyVictoria Daventure, Melissa Bou-Jaoudeh, Emna Hannachi, et al.
European Journal of Immunology|July 2, 2026
Fast Generation of F(Ab')<sub>2</sub> Fragments From Human IgG Using Fc-Fused IgG-Degrading EnzymeEmna Hannachi, Robin V Lacombe, Amélia Trecco, et al.
Haematologica|January 19, 2023
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A miceMelissa Bou-Jaoudeh, Sandrine Delignat, Victoria Daventure, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Medecine Sciences : M/S|January 7, 2020
[Anti-tumor monoclonal antibodies: new insights to elicit a long-term immune response]Claire Deligne, Laurent Gros
Frontiers in Oncology|March 15, 2021
Macrophages and Extracellular Matrix in Breast Cancer: Partners in Crime or Protective Allies?Claire Deligne, Kim S Midwood
Medecine Sciences : M/S|January 29, 2013
[The Janus face of monoclonal antibodies in oncology: passive immunity and vaccination]Claire Deligne, Jean-Luc Teillaud
Journal of Personalized Medicine|April 23, 2022
Personalized Immunotherapies for Type 1 Diabetes: Who, What, When, and How?Claire Deligne, Sylvaine You, Roberto Mallone
Frontiers in Immunology|September 1, 2017
Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?Claire Deligne, Benoît Milcent, Nathalie Josseaume, et al.
Frontiers in Immunology|August 27, 2021
Oral Fc-Coupled Preproinsulin Achieves Systemic and Thymic Delivery Through the Neonatal Fc Receptor and Partially Delays Autoimmune DiabetesNoémie Corcos, Slobodan Culina, Claire Deligne, et al.
Methods in Cell Biology|January 10, 2018
How to detect and purify tenascin-CSean P Giblin, Devadarssen Murdamoothoo, Claire Deligne, et al.
European Journal of Immunology|December 20, 2024
Half-Life Extension of the IgG-Degrading Enzyme (IdeS) Using Fc-Fusion TechnologyVictoria Daventure, Melissa Bou-Jaoudeh, Emna Hannachi, et al.
European Journal of Immunology|July 2, 2026
Fast Generation of F(Ab')<sub>2</sub> Fragments From Human IgG Using Fc-Fused IgG-Degrading EnzymeEmna Hannachi, Robin V Lacombe, Amélia Trecco, et al.
Haematologica|January 19, 2023
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A miceMelissa Bou-Jaoudeh, Sandrine Delignat, Victoria Daventure, et al.
Pageof 2